Article
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Cancer - 1 Jul 2018
Assi Rita, Kantarjian Hagop M, Kadia Tapan M, Pemmaraju Naveen, Jabbour Elias, Jain Nitin, Daver Naval, Estrov Zeev, Uehara Taisuke, Owa Takashi, Cortes Jorge E, Borthakur Gautam
Abstract excerpt
BACKGROUND: Indisulam possesses anticancer properties through down-regulation of various cell-cycle checkpoint molecules, thereby blocking the phosphorylation of retinoblastoma protein and inducing p53 and p21. Indisulam exhibits synergy with nucleoside analogs and topoisomerase inhibitors. METHODS: The authors designed a phase 2 study of indisulam in combination with idarubicin and cytarabine in patients who had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.